National Institute on Drug Abuse. (June 12, 2023). What classes of prescription drugs are commonly misused?. National Institute on Drug Abuse.
Centers for Disease Control and Prevention. (July 17, 2025). Stimulants. Centers for Disease Control and Prevention.
State of Connecticut. Abuse of prescription stimulants. State of Connecticut.
National Center for Biotechnology Information. (January 11, 2011). Stimulant abuse: pharmacology, cocaine, methamphetamine, and inhalant abuse. National Center for Biotechnology Information.
National Center for Biotechnology Information. (June 5, 2020). The role of dopamine in the stimulant characteristics of novel psychoactive substances. National Center for Biotechnology Information.
U.S. Department of Veterans Affairs. (May 20, 2022). Stimulant use disorder. U.S. Department of Veterans Affairs.
National Center for Biotechnology Information. Chapter 3—Medical aspects of stimulant use disorders. National Center for Biotechnology Information.
U.S. Department of Veterans Affairs. Stimulant use disorder clinician’s guide. U.S. Department of Veterans Affairs.
American Society of Addiction Medicine. (April 25, 2023). Stimulant use disorder guideline. American Society of Addiction Medicine.
National Center for Biotechnology Information. (December 1, 2025). The diagnosis and treatment of stimulant-related emergencies. National Center for Biotechnology Information.
Substance Abuse and Mental Health Services Administration. (November 7, 2024). What are stimulants? Side effects, short and long term risks. Substance Abuse and Mental Health Services Administration.
National Center for Biotechnology Information. Chapter 2—How stimulants affect the brain and behavior. National Center for Biotechnology Information.
National Center for Biotechnology Information. (July 22, 2010). The health effect of psychostimulants: a literature review. National Center for Biotechnology Information.
Centers for Disease Control and Prevention. (April 2, 2024). Polysubstance use facts. Centers for Disease Control and Prevention.
National Center for Biotechnology Information. (September 21, 2023). Are you thinking what I’m thinking? Defining what we mean by polysubstance use. National Center for Biotechnology Information.
Agency for Healthcare Research and Quality. Polysubstance use & integrated behavioral health. Agency for Healthcare Research and Quality.
State of Oregon. (March 23, 2026). Polysubstance use. Oregon Health Authority.
U.S. Department of Health and Human Services. (November 14, 2023). Contingency management for the treatment of substance use disorders. Assistant Secretary for Planning and Evaluation.
National Center for Biotechnology Information. (July 31, 2025). Interest in contingency management and reducing stimulant use among people who use drugs. National Center for Biotechnology Information.
Johns Hopkins Bloomberg School of Public Health. (March 22, 2023). Contingency management for treatment of stimulant use disorder and strategies to address polysubstance use. Johns Hopkins Bloomberg School of Public Health.
National Center for Biotechnology Information. Long-term efficacy of contingency management treatment based on reinforcement schedule. National Center for Biotechnology Information.
National Library of Medicine. Patient factors related to early attrition from an outpatient cocaine dependence treatment program. National Library of Medicine.
National Center for Biotechnology Information. (May 5, 2025). The unsolved problem of attrition rates on randomized clinical trials in cocaine use disorder pharmacotherapy. National Center for Biotechnology Information.
National Center for Biotechnology Information. (June 1, 2014). Substance abuse intensive outpatient programs: assessing the evidence. National Center for Biotechnology Information.
Substance Abuse and Mental Health Services Administration. (September 26, 2025). Managing life with co-occurring disorders. Substance Abuse and Mental Health Services Administration.
National Center for Biotechnology Information. (January 1, 2018). Chapter 7—Treatment models and settings for people with co-occurring disorders. National Center for Biotechnology Information.